Business
Mesoblast stumbles as FDA demands more evidence of drug effectiveness – Sydney Morning Herald
The listed biotech’s push to get its flagship product approved in the US has suffered a setback, as the US regulator asks for more evidence of its effectiveness…
The biotech, valued at $1.9 billion, has been striving for a decade to get remestemcel-L approved in the US market. It is also trialling the same product for treatment of coronavirus, in cases where patients are experiencing severe respiratory distress.
The prospect of the coronavirus treatment has sent shares rallying in recent months. In April, Mesoblast shares were sitting at $1.46 but were at $5.08 before going into the trading halt this week.
Chief executive Silviu Itescu said he believed…
-
General13 hours agoMildura man given 28 years to pay $73,000 in unpaid fines and tolls
-
General16 hours agoAustralia’s race to rewire the country amid a global transmission boom is not unique
-
Business17 hours agoI was a huge fan of Fortescue shares, then this happened…
-
General21 hours agoPrincess Diana enters Paris waxwork museum in ‘revenge dress’